Holen Sie sich die Stockscreener-App
69.23
2.73%
1.84
Vorhandelsmarkt:
69.09
-0.14
-0.20%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
RBC Cuts Price Target on DexCom to $100 From $115, Keeps Outperform Rating - MarketScreener
BTIG Adjusts DexCom (DXCM) Price Target Ahead of MedTech Q1 Resu - GuruFocus
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance - MSN
FDA clears Dexcom G7 15 Day - BioWorld MedTech
What Does the Market Think About DexCom? - Benzinga
What to Expect From DexCom's Next Quarterly Earnings Report - TradingView
What To Expect From DexCom's Next Quarterly Earnings Report - Barchart.com
DexCom (DXCM) Anticipates Growth Driven by Strategic Initiatives - GuruFocus
FDA clears Dexcom G7 15-Day continuous glucose monitor - TechTarget
Mizuho Initiates Coverage of DexCom (XTRA:DC4) with Outperform Recommendation - Nasdaq
Dexcom G7 15 Day CGM system cleared by FDA for adults - Investing.com South Africa
Dexcom G7 15 Day CGM System Cleared by FDA - Patient Care Online
DexCom (DXCM) Faces Investor Backlash After Disappointing Earnings ReportHagens Berman - ACCESS Newswire
Dexcom nets FDA clearance for 15-day CGM - MedTech Dive
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With DexcomPanhandle - Panhandle - News Channel
FDA Approves New DexCom Diabetes Device - Yahoo Finance
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch - Benzinga
Stifel maintains DexCom stock Buy rating, $100 target post FDA nod - Investing.com Australia
DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance - Barron's
Dexcom wins FDA nod for 15-day CGM - MassDevice
DexCom (DXCM) Faces Market Challenges Amid Strategic Changes - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in DexCom, Inc. LawsuitDXCM - ACCESS Newswire
DexCom (DXCM) Gains on FDA Approval for G7 15 Day Monitoring Sys - GuruFocus
2 Growth Stocks to Buy in the Tariff-Fueled Market Correction - The Motley Fool
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday - Benzinga
DexCom (DXCM) Receives FDA Clearance for Enhanced Glucose Monito - GuruFocus
DexCom Says G7 15 Day Continuous Glucose Monitoring System Gets US FDA Clearance - MarketScreener
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wea - GuruFocus
Dexcom stock rises on FDA nod for new CGM (DXCM:NASDAQ) - Seeking Alpha
FDA OKs Dexcom G7 15-Day Continuous Glucose Monitor - Medical Product Outsourcing
DexCom shares rise on FDA clearance for new CGM system - Investing.com Australia
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System - Dexcom
Mizuho Initiates Coverage of DexCom (DXCM) with Outperform Recommendation - Nasdaq
What 6 Analyst Ratings Have To Say About DexCom - Benzinga
Mizuho Initiates DexCom at Outperform With $85 Price Target - MarketScreener
FDA Clears Dexcom G7 15 Day for Continuous Glucose Monitoring - Medical Professionals Reference
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DXCM STOCK ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
PODD Stock Benefits From the Launch of Omnipod 5 in Canada - Yahoo Finance
DexCom, Inc. Class Action: Levi & Korsinsky Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024DXCM - ACCESS Newswire
DexCom (NasdaqGS:DXCM) Down 12% As Jon Coleman Becomes Chief Commercial Officer - Yahoo Finance
Citigroup Adjusts DexCom Price Target to $80 From $104, Maintains Buy Rating - MarketScreener
DXCM INVESTIGATION UPDATE: DexCom, Inc. Investors with Losses on their Investment are Notified of Securities Fraud Investigation; Contact BFA Law for Details (Nasdaq:DXCM) - ACCESS Newswire
DXCM INVESTOR UPDATE: Suffer Losses on Your DexCom, Inc. Investment? Contact BFA Law by October 21 about Pending Class Action Lawsuit (Nasdaq:DXCM) - FinTech Futures
ATTENTION DexCom, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
DexCom, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - ACCESS Newswire
DXCM INVESTOR ALERT: DexCom, Inc. Investors are Notified to Contact BFA Law before October 21 Deadline in Class Action Lawsuit - ACCESS Newswire
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - MSN
Why We're Not Concerned Yet About DexCom, Inc.'s (NASDAQ:DXCM) 25% Share Price Plunge - simplywall.st
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt - Morningstar
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in DexCom, Inc. Lawsuit – DXCM - ACCESS Newswire
DexCom stock hits 52-week low at $62.32 amid market shifts - Investing.com
Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time. - The Joplin Globe
2.00%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):